DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Phase 1

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Ulocuplumab
Drug: Ibrutinib

First Posted Date: 2017-07-21

Last Posted Date: 2024-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT03225716

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Phase 1

Recruiting

Conditions: Lymphocytic Leukemia

Interventions: Drug: NeoVax
Drug: Cyclophosphamide
Drug: Pembrolizumab

First Posted Date: 2017-07-17

Last Posted Date: 2024-04-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT03219450

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

Phase 2

Completed

Conditions: Waldenström Macroglobulinemia

Interventions: Drug: Daratumumab

First Posted Date: 2017-06-14

Last Posted Date: 2022-11-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT03187262

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 2 locations

Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Device: Acupuncture

First Posted Date: 2017-05-31

Last Posted Date: 2024-01-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT03170648

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: Binimetinib
Drug: Palbociclib

First Posted Date: 2017-05-30

Last Posted Date: 2024-03-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 34

Registration Number: NCT03170206

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

Phase 1

Recruiting

Conditions: Oligodendroglioma
Ganglioglioma
Glioblastoma
Pylocytic/Pylomyxoid Astrocytoma
Brain Tumor
Glioma
Malignant Glioma of Brain
Astrocytoma
Malignant Astrocytoma
Mixed Oligo-Astrocytoma

Interventions: Drug: rQNestin
Drug: Cyclophosphamide
Procedure: Stereotactic biopsy

First Posted Date: 2017-05-15

Last Posted Date: 2024-08-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 62

Registration Number: NCT03152318

Locations: 🇺🇸
Johns Hopkins University Medical Center, Baltimore, Maryland, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Palbociclib
Drug: Avelumab

First Posted Date: 2017-05-10

Last Posted Date: 2024-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 220

Registration Number: NCT03147287

Locations: 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 19 locations

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: GnRH
Drug: Bicalutamide
Radiation: Salvage radiation
Drug: Abiraterone
Drug: Prednisone
Drug: Apalutamide

First Posted Date: 2017-05-05

Last Posted Date: 2024-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 345

Registration Number: NCT03141671

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 5 locations

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

Phase 2

Terminated

Conditions: Lymphoma
Cancer Survivorship
Autonomic Imbalance

Interventions: Drug: Ivabradine
Drug: Placebo Oral Tablet

First Posted Date: 2017-05-02

Last Posted Date: 2022-02-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT03137537

Locations: 🇺🇸
Boston Children Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Cyclophosphamide and Alemtuzumab In Lymphoma

Phase 1

Terminated

Conditions: Non Hodgkin Lymphoma
High-grade B-cell Lymphoma
Diffuse Large B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Alemtuzumab

First Posted Date: 2017-04-28

Last Posted Date: 2019-01-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT03132584

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy